|  |  | 

India Top Headlines

Relief for SII when court rejects ‘Covishield’ trademark infringement statement | India News


PUNE: A local court rejected an application seeking a court order against the use of ‘Covishield’ as a trademark by the vaccine maker Serum Institute of India (SII), the company said on Saturday.
IBS is producing a coronavirus vaccine called Covishield, jointly developed by the University of Oxford and the British-Swedish company AstraZeneca. The Indian government has purchased 11 million doses of the Covishield vaccine.
While the court order was not immediately available, Cutis-Biotech’s attorney, who had filed the lawsuit, said he would file an appeal in higher court.
On January 4, Cutis-Biotech, a pharmaceutical firm, filed a lawsuit in civil court alleging that it was a previous user of the Covishield brand and tried to prevent SII from using the name.
The SII had told the court that the two companies operate in different product categories and there is no room for brand confusion.
“The court rejected the request,” said SII attorney Hitesh Jain.
Defender Aditya Soni, a lawyer for Cutis-Biotech, said the copy of the order was not yet available, but the operative order was read in court. “We will file an appeal against the order in the higher court,” he said.

Times of India